S158: FINAL RESULT OF TKI DISCONTINUATION TRIAL WITH DASATINIB FOR SECOND ATTEMPT OF TREATMENT FREE REMISSION AFTER FAILING FIRST ATTEMPT WITH IMATINIB: TREATMENT-FREE REMISSION ACCOMPLISHED BY DASATINIB

• D. Kim,
• E. Atenafu,
• D. Forrest,
• I. Bence-Bruckler,
• L. Savoie,
• M.-M. Keating,
• L. Busque,
• R. Delage,
• A. Xenocostas,
• E. Liew,
• P. Laneuville,
• K. Paulson,
• T. Stockley,
• J. Lipton,
• B. Leber

Affiliations

D. Kim

1 Princess Margaret Cancer Centre, Toronto, Canada

E. Atenafu

2 Statistics, Princess Margaret Cancer Centre, Toronto

D. Forrest

3 Vancouver General Hospital, Vancouver

I. Bence-Bruckler

4 Ottawa Hospital Research Institute, Ottawa

L. Savoie

5 University of Calgary, Calgary

M.-M. Keating

6 Queen Elizabeth II Health Sciences Centre, Halifax

L. Busque

7 Hôpital Maisonneuve-Rosemont, Montreal

R. Delage

8 Centre Universitaire d’Hématologie et d’Oncologie de Québec, Quebec

A. Xenocostas

9 London Health Sciences Centre, London

E. Liew

10 University of Alberta, Edmonton

P. Laneuville

11 McGill University Health Centre, Montreal

K. Paulson

12 CancerCare Manitoba, Winnipeg

T. Stockley

13 Division of Clinical Laboratory Genetics, University Health Network, Toronto

J. Lipton

1 Princess Margaret Cancer Centre, Toronto, Canada

B. Leber

14 Juravinstki Cancer Centre, Hamilton, Canada